- Home
- DSM vs PBYI Comparison
DSM vs PBYI Comparison
Compare DSM & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSM
- PBYI
- Stock Information
- Founded
- DSM 1989
- PBYI 2010
- Country
- DSM United States
- PBYI United States
- Employees
- DSM N/A
- PBYI N/A
- Industry
- DSM Investment Managers
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- DSM Finance
- PBYI Health Care
- Exchange
- DSM Nasdaq
- PBYI Nasdaq
- Market Cap
- DSM 304.0M
- PBYI 263.4M
- IPO Year
- DSM N/A
- PBYI N/A
- Fundamental
- Price
- DSM $5.93
- PBYI $5.91
- Analyst Decision
- DSM
- PBYI Strong Buy
- Analyst Count
- DSM 0
- PBYI 1
- Target Price
- DSM N/A
- PBYI $7.00
- AVG Volume (30 Days)
- DSM 161.7K
- PBYI 495.1K
- Earning Date
- DSM 01-01-0001
- PBYI 11-06-2025
- Dividend Yield
- DSM 3.97%
- PBYI N/A
- EPS Growth
- DSM N/A
- PBYI 59.87
- EPS
- DSM N/A
- PBYI 0.74
- Revenue
- DSM N/A
- PBYI $211,968,000.00
- Revenue This Year
- DSM N/A
- PBYI N/A
- Revenue Next Year
- DSM N/A
- PBYI N/A
- P/E Ratio
- DSM N/A
- PBYI $8.02
- Revenue Growth
- DSM N/A
- PBYI N/A
- 52 Week Low
- DSM $4.69
- PBYI $2.32
- 52 Week High
- DSM $6.05
- PBYI $6.07
- Technical
- Relative Strength Index (RSI)
- DSM 45.81
- PBYI 66.48
- Support Level
- DSM $5.95
- PBYI $4.80
- Resistance Level
- DSM $6.01
- PBYI $5.52
- Average True Range (ATR)
- DSM 0.05
- PBYI 0.30
- MACD
- DSM -0.01
- PBYI 0.00
- Stochastic Oscillator
- DSM 16.67
- PBYI 91.53
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.